Dr. SACHDEV SIDHU
Dr. Sidhu joined the Donnelly Centre at the University of Toronto in 2008 after ten years as a principal investigator in the Department of Protein Engineering at Genentech, Inc. Genentech is the leading biotechnology company in the world and is renowned for developing technologies that have enabled the success of antibody drugs in oncology. Within this competitive and innovative environment, the Sidhu lab was at the forefront of new technology development and Dr. Sidhu was personally responsible for leading the development of phage-displayed synthetic antibody libraries. Thus Dr. Sidhu has extensive biotechnology experience and concomitant expertise in commercialization of new reagents and technologies.
Dr. Jayakrishna Ambati, Professor & Vice Chair
Dr. Jayakrishna Ambati is a well renowned Professor & Vice Chair for Research of Ophthalmology, University of Virginia and he is the founder Director of the Center for Advanced Vision Science, University of Virginia. Dr. Ambati completed Biomedical Science from Johns Hopkins University and M.D from the SUNY Downstate Medical Center College of Medicine, Brooklyn New York, in 1994 and has been in practice for more than 20 years. He works in Lexington, KY and specializes in Ophthalmology.
Dr. Ambati serves on the Editorial Board of Investigative Ophthalmology & Visual Sciences, Ophthalmic Research, and is an Associate Editor of Ophthalmology and of Translational Vision Science & Technology. In 2015, he was elected a Fellow of the National Academy of Inventors. He is the first ophthalmologist to win the Doris Duke Distinguished Clinical Scientist Award. In 2014, he received the NIH Director’s Pioneer Award, becoming the first ophthalmologist and the first from an institution in Kentucky, to win the honor. He has got many more awards and honors to his crown.
Dr. Ambati’s scientific aspirations are to identify the molecular mechanisms underlying the development of AMD, determine the triggers of the angiogenic switch that converts this disease from an atrophic to a neovascular phenotype, and to develop novel therapeutics to prevent and treat this blinding condition. He has enrolled for Phase-1 open label dose escalation Clinical Trial for the drug ‘RNA144101’ which he devised for the treatment of Geographic Atrophy (GA). He is renowned for his review on the Phase-I, Phase-2 and Phase-3 Clinical Trials of ophthalmic drugs. He has published in high impact journals like Nature, Nature Medicine, Nature Biotechnology, Cell etc.